Form 4: Director G. Jan van Heek Receives Minerva Stock Options

Minerva Neurosciences director G. Jan van Heek was granted 50,000 stock options as part of his non-employee director compensation.

Summary

• Director G. Jan van Heek acquired 50,000 stock options in Minerva Neurosciences, Inc. (NERV).
• The options have an exercise price of $4.68 per share.
• The grant date for these options is June 3, 2026.
• The options are set to expire on June 2, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• The value of the options is dependent on the future market performance of NERV common stock.
• Vesting is contingent upon the continued service of the director.

Future Outlook

The options vest in four equal quarterly installments starting three months after June 3, 2026, contingent on continued service as a non-employee director.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to incentivize board members and align their interests with long-term company performance.

Comparison to Industry Standards

• The grant of stock options to directors is a common practice among small-cap biotech firms to preserve cash while providing competitive compensation.
• The vesting schedule of one year (four quarterly installments) is consistent with standard board compensation structures.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if options are exercised.

Next Steps

• Vesting of the first 1/4 of the options on September 3, 2026.

Key Dates

Keywords

Minerva Neurosciences, NERV, Form 4, Insider Trading, Stock Options, Director Compensation